- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03217799
Noninvasive Measurement of Blood Coagulation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Overview: The investigators plan to measure the coagulation status with the new sensor in patients who are attending the Coagulation Clinic in Meir Hospital Center. The investigators will measure their coagulation status with the new sensor during the participants' routine clinic visits. During their visits, The participants' care will not be affected or influenced by the results of the data obtained by the new sensor. The accumulated data will be collected and later correlated with their clinical status and with routine clotting parameters that are measured, depending on the type of anticoagulation the participants receive. Specifically, in those receiving warfarin, INR will be assessed during their visit, while in patients receiving direct oral anticoagulants (DOACs), factor Xa activity will be assessed. Inparticipants receiving heparin, PTT will be assessed.
Patients and control subject: Subjects will be recruited from the Coagulation Clinic. The participants will consist of patients attending the clinic for follow-up of their prescribed anticoagulation treatment. Patients to be studied will include subjects receiving warfarin anticoagulation, NOACs, heparin and anti-platelet therapy (aspirin, clopidrogel or other anti-platelet medications). Normal subjects receiving no anticoagulation will also be studied and will serve as the control group.
Protocol: Experimental subjects will be selected from patients attending the Coagulation Clinic. Patients will be seen in the clinic and receive their usual follow-up care. After obtaining informed consent, the participants' coagulation status will be assessed with the new sensor. Patients on warfarin medications will have a venous blood sample obtained (5 ml) for determination of INR. Patients receiving NOACs will have a venous blood sample obtained (5 ml) for determination of Factor Xa activity. At a later date, the coagulation status of the patients as assessed by the new sensor will be compared to the coagulation status as assessed by the standard laboratory methods.
Normal controls will be recruited from hospital personnel. Normal controls will have their coagulation status assessed by the new sensor only. Since normal control are not receiving anticoagulation therapy, blood samples for measurement of INR or factor Xa activity will not be drawn. Normal controls will receive no financial compensation.
Methodology: The pneumatic cuff is attached to the root of the index finger. The sensor cuff is attached several centimeters distal to the pneumatic cuff. Measurement is taken for a 60-second control period, and then the pneumatic cuff is inflated to above-systolic blood pressure (200 mm Hg) for 180 seconds, and measurement is taken during this period of time. The cuff is then deflated, and another 60-second measurement is taken. Data is collected by the measuring device for later analysis.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Orli Avnery, MD
- Phone Number: 972-9-7471352
- Email: AVNERYHO@clalit.org.il
Study Contact Backup
- Name: Martin Ellis, MD
- Phone Number: 972-9-741822
- Email: martinel@clalit.org.il
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Subjects receiving anticoagulant therapy, including warfarin, DOACS, heparin, and antiplatelet drugs
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of coagulability measurement with device vs. Prothrombin time
Time Frame: One day
|
In participants taking coumadin derivatives the results of the coagulation measurement obtained with the device will be compared to results of the Prothrombin time, in seconds, and INR
|
One day
|
Comparison of coagulability measurement with device vs. anti-Xa activity
Time Frame: One day
|
In participants taking coumadin derivatives the results of the coagulation measurement obtained with the device will be compared to results of the anti-Xa activity, measured as anti-Xa units/ml
|
One day
|
Comparison of coagulability measurement with device vs. PTT
Time Frame: one day
|
In participants taking heparin the results of the coagulation measurement obtained with the device will be compared to results of the PTT, seconds
|
one day
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0227
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coagulation Disorder
-
University Hospital, CaenUnknownBlood Coagulation Disorders | Blood Coagulation Disorder With Prolonged Bleeding Time | Blood Coagulation Disorder With Prolonged Coagulation TimeFrance
-
VarmX B.V.RecruitingCoagulation DisorderNetherlands
-
Groupe Hospitalier Paris Saint JosephCompletedCoagulation DisorderFrance
-
Masaryk Hospital Krajská zdravotní a.s.CompletedCoagulation Disorder | Multiple Trauma | Coagulation Defect; Acquired | Coagulation Factor DeficiencyCzechia
-
Cairo UniversityRecruitingCoagulation DisorderEgypt
-
Stony Brook UniversityCompletedCoagulation DisorderUnited States
-
HemoSonics LLCCompleted
-
TakedaTakeda Development Center Americas, Inc.RecruitingCoagulation DisorderUnited States, Spain, Belgium, France, Netherlands
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed
Clinical Trials on Measurement of coagulability of blood
-
GULIN FINDIKOGLUCompletedDiabetes Mellitus, Type 2 | Gait Disorder, SensorimotorTurkey
-
RWTH Aachen UniversityCompleted
-
Rennes University HospitalActive, not recruitingHypertension in PregnancyFrance
-
University Hospital, GrenobleUnknownObstructive Sleep Apnea SyndromeFrance
-
University Hospital, GenevaUniversity of Geneva, SwitzerlandRecruiting
-
Biobeat Technologies Ltd.CompletedHypertension | Blood Pressure DisordersIsrael
-
Institut fur Diabetes Karlsburg GmbHTyson Bioresearch Inc., Kedong 3rd Rd., Zhunan Township, Miaoli County 35053...Completed
-
Plovdiv Medical UniversityRecruitingTrauma | Diagnosis DualBulgaria
-
Institut fur Diabetes Karlsburg GmbHTyson Bioresearch Inc., Kedong 3rd Rd., Zhunan Township, Miaoli County 35053...Completed